[go: up one dir, main page]

MX2021010744A - Metodos para el tratamiento de la perimenopausia y la menopausia. - Google Patents

Metodos para el tratamiento de la perimenopausia y la menopausia.

Info

Publication number
MX2021010744A
MX2021010744A MX2021010744A MX2021010744A MX2021010744A MX 2021010744 A MX2021010744 A MX 2021010744A MX 2021010744 A MX2021010744 A MX 2021010744A MX 2021010744 A MX2021010744 A MX 2021010744A MX 2021010744 A MX2021010744 A MX 2021010744A
Authority
MX
Mexico
Prior art keywords
perimenopause
menopause
methods
treatment
pregnan
Prior art date
Application number
MX2021010744A
Other languages
English (en)
Inventor
Carlos Loya
Nicholas Demartinis
Gabriel Belfort
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of MX2021010744A publication Critical patent/MX2021010744A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a métodos para tratar los síntomas de la perimenopausia o la menopausia utilizando moduladores alostéricos positivos del receptor del ácido y-aminobutírico tipo A (GABA-A PAM), que incluye 3a-hidroxi-38-metoximetil- 21-(1'-imidazolil)-5a -pregnan-20-ona y sus sales.
MX2021010744A 2019-03-04 2020-03-04 Metodos para el tratamiento de la perimenopausia y la menopausia. MX2021010744A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962813498P 2019-03-04 2019-03-04
PCT/US2020/020938 WO2020180955A1 (en) 2019-03-04 2020-03-04 Methods for the treatment of perimenopause and menopause

Publications (1)

Publication Number Publication Date
MX2021010744A true MX2021010744A (es) 2022-01-18

Family

ID=72337303

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010744A MX2021010744A (es) 2019-03-04 2020-03-04 Metodos para el tratamiento de la perimenopausia y la menopausia.

Country Status (8)

Country Link
US (1) US20220125803A1 (es)
EP (1) EP3934655A4 (es)
JP (1) JP2022524505A (es)
CN (1) CN113891715A (es)
AU (1) AU2020231506A1 (es)
CA (1) CA3132728A1 (es)
MX (1) MX2021010744A (es)
WO (1) WO2020180955A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
WO2022165017A1 (en) * 2021-01-28 2022-08-04 Sage Therapeutics, Inc. Use of neuroactive steroids for treatment of sexual dysfunction
WO2022177718A1 (en) * 2021-02-18 2022-08-25 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
WO2022246634A1 (en) * 2021-05-25 2022-12-01 Zhejiang Jiachi Development Pharmaceuticals Ltd. Compositions for treating insomnia and uses thereof
KR20250090325A (ko) 2022-10-21 2025-06-19 고쿠리츠다이가쿠호진 고치다이가쿠 수술 후 섬망의 억제약

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306196A (en) * 2002-04-03 2003-11-16 Wyeth Corp Hormone replacement therapy
WO2005007600A2 (en) * 2003-07-11 2005-01-27 Eisai Co., Ltd. Novel methods using aminobenzoic acid compounds
BRPI0612921A2 (pt) * 2005-06-09 2010-12-07 Euro Celtique Sa composições farmacêuticas de um esteróide neuroativo e métodos de uso do mesmo
GB201315846D0 (en) * 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes
TW202426002A (zh) * 2014-10-16 2024-07-01 美商賽吉醫療公司 用於治療中樞神經系統(cns)病症之組合物及方法
RU2766155C2 (ru) * 2016-03-08 2022-02-08 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применения
US10391105B2 (en) * 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens

Also Published As

Publication number Publication date
JP2022524505A (ja) 2022-05-06
AU2020231506A1 (en) 2021-09-30
WO2020180955A1 (en) 2020-09-10
EP3934655A1 (en) 2022-01-12
US20220125803A1 (en) 2022-04-28
CN113891715A (zh) 2022-01-04
EP3934655A4 (en) 2022-12-21
CA3132728A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
MX2021010744A (es) Metodos para el tratamiento de la perimenopausia y la menopausia.
ZA202204929B (en) Rimegepant for cgrp related disorders
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MY207223A (en) Prodrug modulators of the integrated stress pathway
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
MY208662A (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
EA202090510A1 (ru) Способ лечения бокового амиотрофического склероза придопидином
BR112015023747A2 (pt) métodos para tratar inflamação, doenças autoimunes e dor
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
MX2024008461A (es) Metodos para tratar trastornos linfoproliferativos malignos.
MX2025005941A (es) Moduladores de la actividad tnf-\03b1
EP2661175A4 (en) COMBINATION STEROID AND GLUCOCORTICOID RECEPTORANT AGONIST THERAPY
MX2022011579A (es) Agonistas del receptor farnesoide x para el tratamiento de enfermedades.
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
ZA202203367B (en) Treatment of menstrual cycle-induced symptoms
MX2021003689A (es) Farmacos precursores de antagonistas del peptido relacionado con el gen para calcitonina (gcrp).
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
NO20073104L (no) Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser
IL317293A (en) Online verification of medical devices
EA202193276A1 (ru) Способы лечения холангиокарциномы
BR112021010856A2 (pt) Vibegron para o tratamento de sintomas de bexiga hiperativa
EP4461362A3 (en) Nk1-antagonist combination and method for treating synucleinopathies
EP4234022A3 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
AU2014352875A8 (en) Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis